TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05035888
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT04933292
Drug: Methylprednisolone and Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methylprednisolone combination of mycophenolate mofetil
Study: NCT04933292
Drug: Methylprednisolone and azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methylprednisolone combination of azathioprine
Study: NCT06167486
Drug: SG2918
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SG2918 will be administrated by intravenous infusion every 3 weeks
Study: NCT06021808
Drug: Novel oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
Study: NCT00689806
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
Study: NCT00689806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth once daily for weeks 1-4.
Study: NCT00002139
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03940807
Drug: 11.25mg GnRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.
Study: NCT03940807
Drug: 0.1 mg GnRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.
Study: NCT03940807
Drug: 25 µg transdermal oestradiol
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
Study: NCT05775900
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
Study: NCT06455722
Drug: [68Ga]Ga-P15-041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
Study: NCT05175274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04575519
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
Study: NCT04575519
Drug: ASA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
Study: NCT04575519
Drug: IBU group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
Study: NCT05081921
Drug: HA administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups.
Study: NCT04853927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide 300mg q.d placebo
Study: NCT06556485
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy
Study: NCT06573008
Drug: GP681 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20mg tablets taken orally
Study: NCT06573008
Drug: GP681 Simulant
Normalized name: STAPHYLOCOCCUS SIMULANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching GP681 40mg
Study: NCT06072183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule
Study: NCT06712810
Drug: Axl/Mer/CSF1R Inhibitor Q702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05741476
Drug: DBV712
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBV712 250 mcg epicutaneous system.
Study: NCT05111145
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT04843631
Drug: BFI-751
Normalized name: BFI PWDR,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single use vial, solution
Study: NCT04843631
Drug: EU-STELARA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe, solution
Study: NCT04843631
Drug: US-STELARA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe, solution
Study: NCT05531552
Drug: clinical pharmacy application
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: assessment clinical pharmacist in management of CAD and ICU patients.
Study: NCT04966325
Drug: LC350189 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study: NCT04966325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study: NCT04966325
Drug: LC350189 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study: NCT04926116
Drug: AK3280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT04926116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT05298475
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
Study: NCT05298475
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of PCSK9 inhibitor once a month SC
Study: NCT05298475
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of PCSK9 inhibitor twice a month SC
Study: NCT05817461
Drug: AZD0780 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, fasted
Study: NCT05817461
Drug: [14C]AZD0780 Solution for Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT05817461
Drug: [14C]AZD0780 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, fasted
Study: NCT06466525
Drug: LBT-3627
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic peptide
Study: NCT06466525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT06326606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with no active ingredients
Study: NCT05670912
Drug: Placebo Comparator of Wei Li Bai capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
Study: NCT04770493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (sugar pill)
Study: NCT05770596
Drug: vitamin C group
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
Study: NCT06567002
Drug: MK-6552
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT05588440
Drug: Bridging Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
Study: NCT06290388
Drug: 23ME-01473
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23Me-01473 given by intravenous infusion
Study: NCT06060210
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-ml Saline
Study: NCT04594746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
Study: NCT06710080
Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Normalized name: ICOSAPENT ETHYL 1000 mg ORAL CAPSULE [Vascepa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
Study: NCT06710080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT06714981
Drug: Opioid Free Anaesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received opioid free anesthesia
Study: NCT06714981
Drug: Opioid based Anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received opioid based anesthesia
Study: NCT05245708
Drug: intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be assigned to intranasal placebo.
Study: NCT06719024
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
Study: NCT00010465
Drug: Botanicals
Normalized name: Vicks Children's Botanicals Cough Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06715826
Drug: [68Ga]Ga-NOTA-T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.
Study: NCT06715826
Drug: [18F]F-RESCA-T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.
Study: NCT06715826
Drug: [68Ga]Ga-DOTA-H2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.
Study: NCT06715826
Drug: [18F]F-RESCA-RB14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
Study: NCT06718543
Drug: AK112 with SCRT and CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7day interval, patients will receive 2 cycles of CapeOX chemotherapy combined with AK112 (every 3 weeks; Day 1: Oxaliplatin, 130 mg/m², IV infusion; Day 1: AK112, 20 mg/kg, IV infusion; Day 1 to Day 14: Capecitabine, 850-1000 mg/m², BID, orally).
Study: NCT06718543
Drug: AK112 with SCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of AK112 treatment (Day 1: AK112, 20 mg/kg, IV infusion).
Study: NCT04852458
Drug: Intravenous (IV) hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Study: NCT05582434
Drug: Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two topical treatments will be dispensed and instructions to apply daily to affected area
Study: NCT05582434
Drug: adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
Study: NCT04772209
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
Study: NCT05444738
Drug: oral lollipop with placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
Study: NCT05335252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 caplet 2x daily for 7 days
Study: NCT06370039
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT05515328
Drug: [¹⁴C] BI 685509 formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[¹⁴C\] BI 685509 formulation 1
Study: NCT05515328
Drug: [¹⁴C] BI 685509 formulation 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[¹⁴C\] BI 685509 formulation 2
Study: NCT06452693
Drug: TQA3038 injection/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
Study: NCT06452693
Drug: Nucleotide drugs Control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
Study: NCT05531500
Drug: Injection
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic + steroids
Study: NCT04846231
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
Study: NCT05253417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take four (4) placebo capsules.
Study: NCT06135948
Drug: Extra dose of L-thyroxine, 25 mcg during Ramadan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
Study: NCT04548973
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml normal saline
Study: NCT05030584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally once daily.
Study: NCT06262438
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.
Study: NCT04280003
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous solution, same appearance stem cells solution
Study: NCT05818826
Drug: Hydrocortisone and normal saline solution
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
Study: NCT05634473
Drug: Methacholine Chloride
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agonists
Study: NCT04781816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT06715982
Drug: JAK Inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors for 28 days
Study: NCT06717074
Drug: RBD4059
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBD4059, active drug.
Study: NCT06717074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that is identical in appearance and volume to the doses of active IMP.
Study: NCT06712680
Drug: Test Product HYP-6589
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYP-6589 should be administered orally at the recommended dosage
Study: NCT05731271
Drug: TST003
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV humanized anti-GREM1 monoclonal antibody
Study: NCT05412992
Drug: DMTS Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMTS applied before surgery and worn for 96 hours
Study: NCT05412992
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Study: NCT05780879
Drug: FLAG or CLAG Protocol
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
Study: NCT06487299
Drug: 0.9% NaCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same volume and color as Iron sucrose.
Study: NCT04638751
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitor
Study: NCT04638751
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any form of chemotherapy
Study: NCT06462287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:1 oral capsule time a day for 4 days
Study: NCT06452771
Drug: Placebo (PB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC injection
Study: NCT05788601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05914194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NLS-2 matching placebo tablets orally.
Study: NCT05325203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT06282861
Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Normalized name: TRELEGY ELLIPTA 100/62.5/25MCG INH 30D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product to be used according to specifications. 1 inhalation daily for 12 months
Study: NCT06282861
Drug: Brimica
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Duaklir
Normalized name: Duaklir
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Ultibro
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Ulunar
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Xoterna
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Spiolto Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Yanimo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Broncoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Formatris
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Oslif
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications